Media-no-image

Nordic Life Science Days, NLSDays 2015

Nyheter   •   2015-07-03 10:10 CEST

For the third consecutive year, the Stockholm-Uppsala region is participating with an exhibition booth and a strong presence at NLSDays. With over 900 participants from nearly 30 countries, this two-day event is the Nordic region’s largest life science investment and networking meeting.

Reserve the date now to visit Nordic Life Science Days, which returns to Stockholm on 9-10 September, this year with a clearer focus on and greater involvement from the Baltic states.

“This conference enjoys the broad support of both national and international players. In just three years, it has evolved into the Nordic region’s largest meeting place for those seeking investors or partners in the life science sector, so of course we want to get involved this year as well”, says Camilla Huse Bondesson, Director of Business Development at Uppsala BIO.

For Uppsala BIO and Stockholm Science City Foundation (SSCi), who share a joint exhibition booth, it’s imperative to show what the region can offer researchers, entrepreneurs and investors within life science. This naturally encompasses a vibrant business culture, interesting companies, world-renowned academia and modern infrastructures, as well as a highly developed healthcare system. “We are here to create an interactive meeting place on our home ground, and to concretize our strengths”, continues Camilla, who, together with Per Lek of SSCi, put together the booth programme and engaged the companies involved.

In addition to all the partnering meetings that companies arrange in advance, we offer visitors the opportunity to meet companies and organizations in our booth. This lets them showcase their products or services and enables more spontaneous meetings.

Exactly which companies and organisations you can meet at the Stockholm-Uppsala exhibition booth, as well as how the programme develops, is published and regularly updated on our campaign site:www.nlsdstockholmuppsala.nu

If you want to learn more about Uppsala BIO, SSCi and the opportunities in the region please visit our booth at the conference.

When: September 9-10, 2015
Where: Stockholm Waterfront

More about the overall programme and registration: www.nlsdays.com

For the third consecutive year, the Stockholm-Uppsala region is participating with an exhibition booth and a strong presence at NLSDays. With over 900 participants from nearly 30 countries, this two-day event is the Nordic region’s largest life science investment and networking meeting.

Läs vidare »
Bltqpffypaf9odtixptm

Stockholm Life Newsletter - June 2015

Nyheter   •   2015-06-24 11:19 CEST

Read Stockholm Life Newsletter - June 2015

Media-no-image

Gates Foundation curious about Stockholm’s life science sector

Nyheter   •   2015-06-16 16:30 CEST

The Gates Foundation is curious about Stockholm’s life science sector. During the foundation’s latest visit to Stockholm this June, interest was high in the list of the region’s hottest life science investment opportunities, the Stockholm-Uppsala Life Science Investment Hotlist. The foundation is already planning a follow-up investment trip to Stockholm in July to meet several companies on the list.

- “We’ve seen growing international interest in the Hotlist for a while. The fact that even the Gates Foundation has become aware of the investment opportunities confirms Stockholm’s image as an innovative and leading life science region,” says Ylva Hultman, Stockholm Business Region Development.

The Stockholm-Uppsala Life Science Investment Hotlist is curated by Stockholm Business Region Development. The list is a tool for investors focused on disruptive commercial innovation in life science. The hotlist is updated continuously so stay tuned.

To qualify for the list, the companies must offer a product or service based on unique academic research that will lead to a commercial solution with global potential. They must also have established themselves in the market with a finished product or service, alternatively, be close to the commercialization phase.

The Gates Foundation is curious about Stockholm’s life science sector. During the foundation’s latest visit to Stockholm this June, interest was high in the list of the region’s hottest life science investment opportunities, the Stockholm-Uppsala Life Science Investment Hotlist.

Läs vidare »
Media-no-image

Enhance your competences - join Health Hack Academy 2015

Nyheter   •   2015-06-02 11:11 CEST

Will you develop the next super app, which will keep people happy and healthy? Are you looking for access to unique expertise, bright minds and resources to develop your ideas or solve your problems? Do you want to revolutionize health care? Then you should join  Health Hack Academy, a launch pad for new digital health tools.

Health Hack Academy the meeting place for corporations, entrepreneurs, business developers, coders and gadget geeks, hardware hackers, behavioral psychologist, game developers designers, students, patients, health care professionals, caregivers and others who are looking to transform the future of health care, selfcare and wellbeing. The goal of Health Hack Academy is to support and accelerate the creation of digital health startups originating in a hackathon.

But Health Hack Academy is more than a Hackathon. Health Hack Academy is a co-creative think tank, an exciting competition and a hands-on, learning innovation program. The Hackathon, which is the core activity, takes place during the weekend September 12-13, 2015. During a few workshops in September 2015 the ideas are scrutinized, prototypes are built, tested, re-built and then finally pitched in front of an international crowd at  Digital Health Days September 23-24. And the process is coached by experts within service design, prototyping, business development and presentation techniques.

Do you want your challenges solved?
As a company or organization with a challenge related to health care, self care or well being, Health Hack Academy welcomes you as a Challenge Partner. This is your opportunity to engage bright minds to build and refine novel solutions.

As a company or organization with a technology platform that can be used to build products and services related to health care, self care or well being, Health Hack Academy welcomes you as a Technology Partner.

Read more at: healthhackacademy.se/

Do you want to solve challenges?
We need your help to solve the challenges that really matter, for all of us.

Read more and sign up for news to make sure you won’t miss when registration opens:  http://healthhackacademy.se/

Please contact Andreas Namslauer, andreas.namslauer@ssci.se, +46 70 533 77 86, if you have any questions or want to join as Partner

Health Hack Academy 2015 is organized by Stockholm Science City Foundation together with Red Dot Award winning design company:  Veryday and the leading European organisation for Innovation and Education in the field of Information and Communication Technologies: EIT- ICT Labs

​Will you develop the next super app, which will keep people happy and healthy? Are you looking for access to unique expertise, bright minds and resources to develop your ideas or solve your problems? Do you want to revolutionize health care? Then you should join Health Hack Academy, a launch pad for new digital health tools.

Läs vidare »
Media-no-image

Imaging study highlighted at ASCO reveals many women may receive wrong HER2 therapy

Nyheter   •   2015-06-01 15:34 CEST

Solna, June 1, 2015. – Affibody AB today announced the presentation of a clinical study at American Society of Clinical Oncology (ASCO).

In breast cancer patients, knowledge of the HER2 (human epidermal growth factor receptor type 2) status is crucial to predict whether an individual will respond to HER2-targeted therapy. Such therapy, e.g. Genentech’s Herceptin® (trastuzumab) has greatly benefitted breast cancer patients over the last decade and is regarded as the beginning of a new era of personalized medicine. However, an important study presented at ASCO in Chicago today with a new non-invasive imaging agent, shows that there are often unexpected changes in HER2 status from the primary tumor during metastatic disease, which may lead to women receiving the wrong therapy.

In the study, sixteen women with known metastatic breast cancer and on-going treatment were included and underwent PET/CT to identify viable metastases. Twelve had HER2- positive primary tumors and four were included as HER2-negative controls. The PET imaging agent ABY-025 is based on an Affibody® molecule that binds strongly to HER2.The rapid clearance of ABY-025 from blood and normal organs allowed HER2 assessment within 2-4 hours. The ABY-025 assessment prompted the treating physician to modify treatment in several patients.

“We believe this study has major implications for women undergoing HER2-targeted therapy since it clearly shows that their HER2 status in the metastasis can change or be heterogenous, and thus necessitate a change in treatment,” says David Bejker, CEO of Affibody. “We now hope that imaging using this new agent will become routine for metastatic breast cancer patients.”

Enquiries

David Bejker, CEO +46 706 454 948
Johan Stuart CFO +46 706 644 096

About Affibody

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the halflife extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Biotest, Daewoong, Daiichi Sankyo, Swedish Orphan Biovitrum, GE, Nordic Nanovector, and Thermo Fisher.

Affibody AB today announced the presentation of a clinical study at American Society of Clinical Oncology (ASCO).

Läs vidare »
Media-no-image

​Affibody AB and Biotest AG enter into a Research License and Option Agreement regarding the Albumod™ platform

Nyheter   •   2015-06-01 15:32 CEST

Dreieich, Germany and Solna, Sweden – Biotest AG and Affibody AB today announced that the companies have signed a Research License and Option Agreement.

The agreement relates to the use of Affibody’s proprietary Albumod™ platform, which is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life, with compounds from Biotest’s portfolio of proprietary molecules.

Affibody’s CEO, David Bejker, said: “Biotest with their vast experience in development of protein based drugs is an ideal partner for our Albumod™ platform and we are very pleased to announce this agreement today. This announcement further illustrates that our license driven business model can continue to deliver new collaborations”.

Affibody will receive up-front and milestone payments as well as royalties on sales for licensing of the Albumod™ platform. Further details of the agreement have not been disclosed.

Enquiries

David Bejker, CEO +46 706 454 948
Johan Stuart CFO +46 706 644 096

About the Albumod™ platform

Affibody’s Albumod™ technology is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life, thereby allowing for less frequent dosing and lower peak concentrations in blood with a decreased risk for adverse events. In addition to these patient safety benefits, the overall treatment costs are reduced. For more information please refer to: www.affibody.se.

About Affibody

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the halflife extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Daewoong, Daiichi Sankyo, Swedish Orphan Biovitrum, GE, Nordic Nanovector, and Thermo Fisher.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forwardlooking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

Biotest AG and Affibody AB today announced that the companies have signed a Research License and Option Agreement.

Läs vidare »
Bltqpffypaf9odtixptm

Stockholm Life Newsletter - May 2015

Nyheter   •   2015-05-28 10:29 CEST

Stockholm Life Newsletter - May 2015

Bltqpffypaf9odtixptm

Stockholm Life Newsletter - April 2015

Nyheter   •   2015-04-29 11:03 CEST

Läs det senaste nyhetsbrevet från Stockholm Life.

Media-no-image

Norra Stationsgatan i helt ny tappning

Blogginlägg   •   2015-04-02 12:46 CEST

Under 2014 har ett tiotal fastighetsägare tillsammans med Stockholm stad arbetat fram en handlingsplan för Norra Stationsgatan. Arbetet har letts av Place Development Group, en konsultgrupp som är specialister inom utveckling av städer, platser och destinationer.

Syftet har varit att skapa en gemensam vision som fastighetsägare, exploatörer och Stockholms stad kan arbeta efter för att skapa en attraktiv destination. Det är ett långsiktigt arbete där samsyn och helhetsbild är avgörande för gatans framgång.

Arbetet har genomförts genom en serie workshops där gatans inriktning och position har diskuterats fram. När samtliga aktörer aktivt arbetar tillsammans skapas genomförandekraft som ger goda förutsättningar för att uppnå en attraktiv helhetsupplevelse med platsen.

Norra Stationsgatan ska bli en av Stockholms mest intressanta destinationer där Hagastaden möter Vasastaden. Målet är att utveckla nya och befintliga kvarter för att skapa bestående värden för kommersiella aktörer, boende och besökare.

Det kommer att bli en inbjudande och kontrastrik destination med matupplevelser, levande stråk och ett kvalitativt serviceutbud. En tillgänglig och händelserik del av Hagastaden med konst, kultur & design.

Den gemensamma plattformen ligger till grund för det fortsatta arbetet som kommer att bli en spännande resa.

​Under 2014 har ett tiotal fastighetsägare tillsammans med Stockholm stad arbetat fram en handlingsplan för Norra Stationsgatan. Arbetet har letts av Place Development Group, en konsultgrupp som är specialister inom utveckling av städer, platser och destinationer.

Läs vidare »
Bltqpffypaf9odtixptm

Stockholm Life Newsletter - March 2015

Nyheter   •   2015-03-26 09:53 CET

Läs det senaste nyhetsbrevet från Stockholm Life.

Kontaktpersoner 4 kontaktpersoner

  • Presskontakt
  • Kommunikationschef
  • Marknadsföring och kommunikation
  • anna.frejd@ssci.se
  • +46 705 39 00 79
  • +46 8 522 110 40
Marketing and Communications Director

Om Stockholm Life Solna-Stockholm

Stockholm Life Solna-Stockholm är ett nav för forskning och utveckling inom life science i Hagastaden.

Stockholm Life är en del av ett nytt stadsområde som växer fram i gränsen mellan Solna och Stockholm – i storstadens puls och med naturen om hörnet. Inom området görs stora investeringar i bostäder, life science-fastigheter och kommunikation för att fylla det med service, kultur och möjligheter till rekreation.

Adress

  • Stockholm Life Solna-Stockholm
  • STOCKHOLM SCIENCE CITY Wenner-Gren Center, Sveavägen 166
  • 113 46 Stockholm
  • Vår hemsida